Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Pharmacogenomics. 2017 Oct;18(15):1381-1386. doi: 10.2217/pgs-2017-0137. Epub 2017 Oct 6.

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Author information

1
Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
2
Sema4, a Mount Sinai venture, Stamford, CT 06902, USA.
3
The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
4
Department of Pharmacy, the Mount Sinai Medical Center,  NY 10029, USA.
5
Icahn Institute for Genomics & Multiscale Biology, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
6
Mount Sinai Faculty Practice Associates Primary Care Program, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
7
Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
8
The Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
9
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
10
Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, UMRS_1166 ICAN, Institute of Cardiometabolism & Nutrition, AP-HP, Pitié-Salpêtrière Hospital, Institute of Cardiology, Paris, France.
11
Berlin Institute of Health, Berlin, Germany.
12
Department of Psychiatry & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, NY 10029, USA.
13
Department of Medicine, Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, NY 10029 USA.

Abstract

For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

KEYWORDS:

Icahn School of Medicine at Mount Sinai; clinical implementation; discovery; education; genetic testing; pharmacogenetics; pharmacogenomics

PMID:
28982267
PMCID:
PMC5694020
DOI:
10.2217/pgs-2017-0137
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center